Showing results (1-10 of 246) with videos related to
Sort By:
Pageof 25
Seminars in Oncology|March 10, 2020
Locally advanced rectal cancer: The past, present, and futureBryan Oronsky, Tony Reid, Chris Larson, et al.Seminars in Oncology|June 11, 2020
Just eat it: A review of CD47 and SIRP-α antagonismBryan Oronsky, Corey Carter, Tony Reid, et al.International Journal of Molecular Sciences|December 11, 2022
What Exactly Is Inflammation (and What Is It Not?)Bryan Oronsky, Scott Caroen, Tony ReidJournal of Drug Targeting|May 21, 2021
Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomasBryan Oronsky, Tony Reid, Pedro CabralesAmerican Journal of Cancer Research|August 15, 2022
AdAPT-001, an oncolytic adenovirus armed with a TGF-β trap, overcomes in vivo resistance to PD-L1-immunotherapyChristopher Larson, Bryan Oronsky, Tony ReidCase Reports in Oncology|April 3, 2023
Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma PatientSantosh Kesari, Jeannie Williams, Erica Burbano, et al.Biochemical and Biophysical Research Communications|April 17, 2014
Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapyShoucheng Ning, Mark Bednarski, Bryan Oronsky, et al.American Journal of Cancer Research|May 9, 2022
The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenograftsTony Reid, Bryan Oronsky, Nacer Abrouk, et al.International Journal of Medical Sciences|October 14, 2022
Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in RatsScott Caroen, Bryan Oronsky, Tony Reid, et al.Journal of Investigative Medicine High Impact Case Reports|August 8, 2018
Case Series: Abscopal Benefit of Surgery in 3 Immunotherapy-Treated Patients With Unresectable CancerBryan Oronsky, Chris Larson, Tony R Reid, et al.Pageof 25